Investigating how tobacco carcinogens and fructose intake affect lung cancer progression, suggesting new therapeutic targets.
Although tobacco smoking is the leading cause of lung cancer (LC), excessive sugar intake has also emerged as a potential risk factor, yet its mechanistic contribution remains poorly defined.In this study, we investigated how high-fructose intake modulates the tobacco carcinogen-induced LC progression.Co-exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and benzo[a]pyrene (NNK and BaP; collectively referred to as NB) combined with a high-fructose diet markedly accelerated tumor progression in multiple mouse models, including Kras G12D/+ -driven LC and LKB1-deficient (LKB1 KO ) lung tumors.NB-induced LC progression was suppressed by restricting glucose metabolism, indicating a metabolic dependency.Mechanistically, NB exposure stimulated transcriptional programs that promote monocyte/macrophage recruitment within the tumor microenvironment and enhanced fructose uptake through both transcriptional and post-transcriptional upregulation of fructose transporters, including glucose transporter 8 (GLUT8).This metabolic reprogramming increased acetylation of histones and signal transducer and activator of transcription 3 (STAT3), leading to transcriptional upregulation of genes governing macrophage differentiation and M2 polarization.Analysis of human LC samples revealed enrichment of pro-metastatic IL-10 + and VEGFA + M2 macrophages, which correlated with poor clinical outcomes.Collectively, these findings demonstrate that NB-driven fructose metabolism induces epigenetic reprogramming of macrophages to promote LC progression and identify pro-metastatic M2 macrophages as potential prognostic biomarkers and therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Ahn et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: